A Multiple Dose, Randomised, Double-blind, Placebo-controlled, Multiple Site Study of Anti-C5a Receptor Antibody (NNC 0151 0000 0000) in Subjects With Systemic Lupus Erythematosus (SLE).
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2014
At a glance
- Drugs NN 8209 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 14 Aug 2014 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 02 Feb 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 12 Dec 2009 New trial record